skip to content


Indivior agrees settlement with Mylan

25 September 2017 07:39

Indivior has confirmed that its US subsidiary, Indivior Inc, together with Monosol Rx, had entered into a settlement agreement with Mylan Pharmaceuticals, Mylan Technologies and Mylan NV resolving patent litigation related to SUBOXONE (buprenorphine and naloxone) Sublingual Film.

It said the litigation had been pending in the US District Court for Delaware and resulted from Mylan's submission of an abbreviated new drug application (ANDA) to the US Food & Drug Administration seeking approval to market generic versions of SUBOXONE Film.

It said the terms of the settlement were confidential.

Indivior chief executive Shaun Thaxter said: 'We are pleased to have amicably settled all outstanding litigation with Mylan.

'The agreement at once reflects our desire to create further certainty for Indivior and underscores the strength of our intellectual property.

'Further, as recently demonstrated with our newly granted '454 patent, we expect to expand the intellectual property estate for SUBOXONE Film and vigorously assert and defend it.'

Story provided by

Related Company: INDV

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.